Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China’s NMPA clears Foresee’s Camcevi 42 mg for prostate cancer
Camcevi 42 mg is a ready-to-use, six-month subcutaneous depot formulation of leuprolide mesylate for advanced prostate cancer treatment. Credit: NMK-Studio/Shutterstock.com.
Camcevi 42 mg is a ready-to-use, six-month subcutaneous depot formulation of leuprolide mesylate for advanced prostate cancer treatment. Credit: NMK-Studio/Shutterstock.com.